Skip to content

6 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Lipoprotein(a) variability in high CV risk patients with hypertriglyceridemia and controlled LDL-C on statin therapy – REDUCE-IT Lp(a) Variability

Therapeutics that dramatically lower lipoprotein(a) (Lp(a)) currently in phase 3 testing have enrolled participants with concentrations above certain thresholds, e.g., ≥70 mg/dL or ≥150 nmol/L. Although repeated testing of Lp(a) is generally viewed as unnecessary due to the fact that concentrations are primarily...

M. Szarek, D. L. Bhatt, M. Miller et al. · 0 citations
Nov 2026

Abstract 10036: Apolipoproteins and Cardiovascular-Kidney-Metabolic-Biomarkers Each Add to Prediction of Residual Cardiovascular Disease Risk After Acute Coronary Syndrome: Insights from the ODYSSEY OUTCOMES Trial

Background: Residual cardiovascular risk persists in acute coronary syndrome (ACS) despite intensive lipid-lowering therapy. We investigated whether extended biomarker profiling, including a 9-plex apolipoprotein panel (with apoE phenotyping) and 11 CE-marked emerging Cardiovascular-Kidney-Metabolic (CKM) parameters...

N. V. van Neer, J. Jukema, L. Ruhaak et al. · 0 citations
Review Open access Oct 2026

Design and baseline data of AZURE-HeFH, a phase 3 study assessing the effect of the oral PCSK9 inhibitor laroprovstat on LDL cholesterol in patients with heterozygous familial hypercholesterolaemia

Patients with heterozygous familial hypercholesterolaemia (HeFH), if untreated or undertreated, are characterised by lifelong exposure to elevated low density lipoprotein cholesterol (LDLc) levels, associated with a markedly increased risk of atherosclerotic cardiovascular disease (ASCVD). Recent surveys, however...

E. Stroes, R. S. Rosenson, R. Santos et al. · 0 citations
Review Open access Oct 2026

Effect of Obicetrapib on Glycaemia and New-Onset Diabetes: Pooled Analysis of BROADWAY/BROOKLYN and an Updated Meta-analysis of CETP Inhibitor Trials.

AIMS New-onset diabetes (NoD) is a recognised effect of statin therapy potentially influencing acceptance of intensive LDL-C-lowering. In contrast, cholesteryl ester transfer protein (CETP) inhibition has been associated with lower NoD risk in earlier trials. We assessed the effect of the highly selective CETP inhibito...

J. Brandts, M. Szarek, S. J. Nicholls et al. · 0 citations
Open access Oct 2026

Cholesteryl ester transfer protein (CETP) inhibition and high-density lipoprotein particle composition: consequences for atherogenesis and neurodegeneration

Cholesteryl ester transfer protein (CETP), required for transferring triglyceride from very-low-density lipoprotein in exchange for cholesteryl ester from high-density lipoprotein (HDL), is also involved in lipophilic antioxidant exchange. We aimed to determine the effects of the next generation potent CETP inhibitor...

Eric J. Niesor, M. Ditmarsch, Serge Rezzi et al. · 1 citation
Open access Sep 2026

Lipoprotein (a) variability in high cardiovascular risk individuals with hypertriglyceridemia and controlled LDL-C on statin therapy in REDUCE-IT.

Findings suggest multiple assessments may be warranted for Lp(a)-related risk stratification and, potentially, eligibility for Lp(a)-targeted treatments, particularly among individuals with relatively high concentrations or certain demographic and clinical characteristics.

M. Szarek, Deepak L. Bhatt, Michael Miller et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.